NCT01671956View on ClinicalTrials.gov

Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis

PHASE2UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

March 31, 2019

Conditions
Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Interventions
BIOLOGICAL

Bertilimumab

IV infusion over 30 minutes, at Day 0, Day 14 and Day 28

BIOLOGICAL

Placebo

IV infusion over 30 minutes, at Day 0, Day 14 and Day 28

Trial Locations (6)

44299

RECRUITING

Meir Medical Center, Kfar Saba

58100

RECRUITING

Wolfson Medical Center, Holon

64239

RECRUITING

Sourasky-Ichilov Tel Aviv Medical Center, Tel Aviv

91031

RECRUITING

Shaare Zedek Medical Central, Jerusalem

91120

RECRUITING

Hadassah Ein Kerem, Jerusalem

Unknown

RECRUITING

HaEmek Medical Center, Afula

Sponsors
All Listed Sponsors
lead

Immune Pharmaceuticals

INDUSTRY